Overview of Anastrozol Bluefish
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Anastrozole |
| Form | Tablets (Oral administration) |
| Pharmacological class | Selective Non-Steroidal Aromatase Inhibitor |
| Common Use | Hormonal/Endocrine Therapy |
| Origin | Synthetic 1,2,4-Triazole Derivative |
What is Anastrozol Bluefish?
Anastrozol Bluefish: Definition and Pharmacological Classification
Anastrozol Bluefish is a prescription-only, generic medicine manufactured by Bluefish Pharma. Its sole active ingredient is Anastrozole. This medication is classified as a selective non-steroidal aromatase inhibitor, positioning it within the broader group of antineoplastic agents used for hormonal therapy. The formulation is presented as tablets intended for oral administration.
Its classification is crucial as it dictates the drug's specialized role, which is clinically recognized for its part in managing hormone-sensitive conditions. As a generic, it provides the identical therapeutic benefit as the original compound, focusing specifically on the hormonal cascade.
Composition, Origin, and Therapeutic Type
The active compound, Anastrozole, is a synthetic 1,2,4-triazole derivative distinguished by its non-steroidal structure. Anastrozol Bluefish is a single-ingredient product, comprising Anastrozole and the necessary pharmaceutical excipients for its solid oral dosage form.
This drug is categorized as endocrine (hormonal) targeted therapy, which focuses on modifying hormone activity within the body. Pharmacological studies confirm the compound’s mechanism of suppressing a specific enzyme, making it a critical treatment for adult patients, particularly postmenopausal women, whose estrogen production relies heavily on this pathway.
High-Level Purpose: Suppression of Estrogen
The fundamental purpose of Anastrozol Bluefish is to achieve significant estrogen biosynthesis suppression. It works by competitively blocking the aromatase enzyme, which is responsible for converting androgen hormones into estrogen in peripheral tissues. By inhibiting this critical enzyme, the medication dramatically lowers the level of circulating estrogen concentrations in the bloodstream. This targeted physiological action forms the basis of its therapeutic use, providing a specific mechanism to mitigate the growth stimulation of tissues sensitive to estrogen.
Regulatory References






